These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1888640)

  • 1. The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.
    Ferry N; Bernard N; Pozet N; Gardes E; Bruguier M; Cuisinaud G; Sassard J
    Br J Clin Pharmacol; 1991 Jul; 32(1):39-44. PubMed ID: 1888640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of the enantiomers of atenolol.
    Boyd RA; Chin SK; Don-Pedro O; Williams RL; Giacomini KM
    Clin Pharmacol Ther; 1989 Apr; 45(4):403-10. PubMed ID: 2702798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of biological equivalence of two atenolol preparations.
    Wolf-Coporda A; Plavsić F; Vrhovac B
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):567-71. PubMed ID: 3323073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of orange juice on the pharmacokinetics of atenolol.
    Lilja JJ; Raaska K; Neuvonen PJ
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):337-40. PubMed ID: 15983823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment.
    Vree TB; Van den Biggelaar-Martea M; Van Ewijk-Beneken Kolmer EW; Hekster YA
    Pharm World Sci; 1993 Aug; 15(4):165-70. PubMed ID: 8220301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
    Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
    Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of two brands of atenolol following a single oral administration.
    Irshaid YM; Rawashdeh NM; Awwadi FF; Kato MK
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):457-61. PubMed ID: 8897086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.
    Vree TB; van den Biggelaar-Martea M; van Ewijk-Beneken Kolmer EW; Hekster YA
    Pharm World Sci; 1993 Jun; 15(3):98-104. PubMed ID: 8348113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics and pharmacodynamics of tablet, suspension and paste formulations of atenolol in cats.
    Khor KH; Campbell FE; Charles BG; Norris RL; Greer RM; Rathbone MJ; Mills PC
    J Vet Pharmacol Ther; 2012 Oct; 35(5):437-45. PubMed ID: 21985149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.
    Vree TB; Wijnands WJ; Baars AM; Hekster YA
    Pharm Weekbl Sci; 1988 Oct; 10(5):193-9. PubMed ID: 3205675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
    Wan SH; Koda RT; Maronde RF
    Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia.
    Telatyńska B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
    Pol J Pharmacol; 2003; 55(1):81-9. PubMed ID: 12856830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.
    Martins ML; Pierossi MA; Moraes LA; Ribeiro W; Abbib Júnior E; Mendes GB; Poli A; De Nucci G; Muscará MN
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):324-8. PubMed ID: 9266287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence of two tablet formulations of atenolol after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Xanthakis I; Nikolaidis N; Njau SN
    Arzneimittelforschung; 2000 Mar; 50(3):243-7. PubMed ID: 10758775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.
    Lewis R; Maclean D; Ioannides C; Johnston A; McDevitt DG
    Br J Clin Pharmacol; 1988 Jul; 26(1):53-9. PubMed ID: 2904825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability of two brands of atenolol 100 mg tablets (Tensotin and Tenormin) in healthy human volunteers.
    Najib NM; Idkaidek N; Adel A; Mohammed B; Al-Masri S; Admour I; Alam SM; Dham R; Qumaruzaman
    Biopharm Drug Dispos; 2005 Jan; 26(1):1-5. PubMed ID: 15578769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans.
    Drozdzik M; Domanski L; Wojcicki J; Pudlo A; Machoy P
    J Clin Pharmacol; 2003 May; 43(5):524-8. PubMed ID: 12751273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)].
    Flouvat B; Bazin M; Lucsko M; Roux A; Guedon J
    Ann Biol Clin (Paris); 1978; 36(4):339-46. PubMed ID: 32816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampicin on the pharmacokinetics of atenolol.
    Lilja JJ; Juntti-Patinen L; Neuvonen PJ
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):555-8. PubMed ID: 16700816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
    Telatyńska-Smieszek B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
    Pol Arch Med Wewn; 2004 Jan; 111(1):45-51. PubMed ID: 15088420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.